IBI-333 / Innovent Biologics - LARVOL DELTA

A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1 | N=17 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting ➔ Completed

Trial completion • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1 | N=17 | Active, not recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2024 ➔ Apr 2024

Enrollment closed • Trial completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration (PRNewswire-Asia) - "Innovent Biologics...announced that the first participant with neovascular age-related macular degeneration (nAMD) has been successfully dosed in the phase 1 clinical trial of IBI333, a recombinant anti-VEGF–A and anti-VEGF-C bispecific fusion protein. This phase 1 study (CTR20222674) aims to evaluate the safety and tolerability of intravitreal injection of IBI333 in participants with nAMD."

Trial status • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology

Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

New P1 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration